Recent

% | $
Quotes you view appear here for quick access.

BCE Inc. Message Board

jagan1961 603 posts  |  Last Activity: Apr 14, 2015 10:02 PM Member since: Oct 31, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Someone is deliberately keeping the price low with the help of these Crooks. Everytime a positive news breaks out it is being deliberately sidelined and shorting begins with a vengeance.

    Definitely yesterday many individual shareholders might have burnt big time and it is scary too. For seasoned ones it is fine, the buyout looms very large right now.

    The company don't need any money right now and they have 150 MLN on hand, which will last atleast for 18 months, by which time they will have couple of products in the market place.

    ARC-520 can be manufactured at a commercial scale right now. Having said that $25-30 buyout is not ruled out right now.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Did he go to China and found out 3 mg/4 mg data is bad? Leaked out, then why $9, it should be $4 then.

    If you believe in these analysts then you are doomed.

    GLTA LONGS!

    Sentiment: Strong Buy

  • What a #$%$ the Jeffereies are? Whom they are supporting here?
    The WS is full of croooks and we small investors are just pans with these #$%$s games.

    Jefferies downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Hold with a price target of $9.00 (from $30.00), in assumed coverage.
    Analyst Eun Yang commented, "HBV market is large; roughly ~2x size of HCV market on WW # pts. While potential for HBV functional cure with lead product ARC-520 exists, on lower-than-expected early efficacy data, we await to see multi-dosing data for potential deeper responses (vs. single-dose). ARWR is to begin multi-dosing Ph2b in ~May 2015 (at 1mg/kg, 1x monthly for 3 months, n=12)."
    The firm raised FY 2015 EPS from ($1.45) to ($1.42) and cut FY 2016 EPS from ($0.43) to ($1.43).
    For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
    Shares of Arrowhead Research closed at $8.00 yesterday.

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 14, 2015 7:41 AM Flag

    Shorts are all over ARWR, who is lending them this many shares is anybody's guess. Most of the shorted shares are not even reported.

    Hope Anzilo releases 3mg/4 mg data soon, without which the shares will move sideways.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Even though 70%+ shares owned by the institutions and most of the brokerages don't allow to be traded in Margin, I'm puzzled with the way shorts piling on this one. Yesterday's 9 MLN share volume was mostly on the Sell side and with just 18 MLN shares float, how can they churn this much of volume is anybody's guess.

    It is going to be very difficult task for the longs. I used to own a company like Cyclacel, where Ramboti's used to pop up (cancer cure with a pill) and there are folks who used to post great things about the company, ultimately the stock is trading in pennies.

    ARWR needs to release 3mg/4mg data to the market to see, what sort of KD is being achieved, without which this is going to be very tough to determine the movement of this stock. It might even be Risk free to buy after the release of 3mg/4 mg data.

    If the 3mg/4mg data is good and achieves incremental KD, then the stock will move past 2 digits otherwise the stock might fall back below previous lows under $4.

    The way in which the Shorts are piling on this one, I suspect even if there are good results you can scoop the shares much cheaper than its worth even after their 3mg / 4mg positive results, since shorts will not allow the shares to move up until they cover all their shares.

    I'm currently neutral on this one, neither adding to my position nor selling anything.

    GLTA LONGS!

    Sentiment: Strong Buy

  • I suspect this seems to be the case. Look at those who bought today at high 8's and 9's. Unnecessarily the small shareholders lost a ton.

    Looks to me the Anzilo is hand in glove with the institutions to create a false uptick and then kill the individual shareholders.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    Today's news is underwhelming....

    by carrix_fool Apr 13, 2015 2:21 PM
    jagan1961 jagan1961 Apr 13, 2015 2:30 PM Flag

    Each dose of ARC-520 has effective till 45 days and upto 2 months. 30 days is very good, even ARWR would not have asked anything of shorter duration.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Looks like some other institutions accumulated more shares today. Watch for the filing.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    Such small PPS action

    by tltrooper Apr 13, 2015 11:50 AM
    jagan1961 jagan1961 Apr 13, 2015 12:29 PM Flag

    14 MLN shares shorted already. For the past 3/4 days if you look at the trading pattern there are more shorted shares. Even today it is overwhelming short position, how long they can generate this many phantom shares.

    They received 1 mg approval long ago, only 2 mg/4 mg multi dosage trial was on Hold. Today they can start multi-dosing trials 2 -4 mg.

    Everything is cleared for ARC 520 trials, incremental KD and functional cure with Multi-dosing trial is the Goal here.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 13, 2015 12:07 PM Flag

    In connection with an IND filed in December 2014, Arrowhead proposed a parallel design multiple-dose Phase 2b study testing doses of 2 mg/kg and 4 mg/kg simultaneously. In January 2015, the FDA notified the Company that a partial clinical hold had been placed on the program. In order to proceed with the proposed parallel design study, the FDA requested that the Company provide additional information including data from the single-dose Phase 2a study in patients who receive 1-4 mg/kg ARC-520, data from an ongoing multiple-dose non-clinical study, and data from Heparc-2004 which is now cleared to begin.

    I think they are starting with 1 mg/kg however they are allowed to go for 2 & 4 mg /kg now.

    GLTA LONGS!

    Sentiment: Strong Buy

  • It is worth a huge money when both ARC 520 and ARC AAT comes out. With the NVS portfolio acquisition you have 3 immediate Drug candidates in the Pipeline and another 30 Potential candidates.

    That is huge folks!

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    Closing the Gap.

    by mudbug021 Apr 13, 2015 11:44 AM
    jagan1961 jagan1961 Apr 13, 2015 11:50 AM Flag

    No one is frustrated here. Very clear mission here. It is going to take 3/4 months Sep/Oct timeframe for the 3mg/4 mg single dosage results and by year end the Multi-dosage trials.

    There are only 60 MLN shares O/3 and 14.5 MLN shares were short then. Add another 4-5 million last week and another 3+ mln today.

    Shorts have a hell of a problem here to cover. On top of it, I'm seeing a possible Buyout or a Billion $+ agreement here for ARC 520 development here.

    A buyout @25 $ will make it 1.5 BLN, gives GIld or anyone (Roche) to get 10+ bln $ a year revenue potential.

    Let the Bidding war starts here.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 13, 2015 11:36 AM Flag

    that was mudbug scamster alias I suspect!

    There is no way GILD or any other competitor is going to stay idle here. THis is one of the very positive news. This approval ensures ARWR will achieve FC once PH2 multi-dosage trials are completed.

    This is worth 10's of billions of $ worth of business.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 13, 2015 11:17 AM Flag

    I'm always of the opinion with the PPS being this low there is no way Competitors are lying low.

    Today's news and the FDIC approval for 2mg/4 mg dosage proves, FDIC is satisfied with the data they received from Arrowhead along with certain non-clincal trial data.

    It is a very significant news and shorties are trying to spin anyway they want, they are doomed here ON!

    GLTA LONGS!

    Sentiment: Strong Buy

  • Good luck to ALL LONGS! THe issue is they are dispensing as if there is no tomorrow.

    I'm pretty sure the stock will trade $100+ in 5-6 months time frame. 3/4 Mg single dosage and 1 mg multi-dosage should be available. 2/4 Mg multi-dosage will be completed in 9 months time frame for a FC!

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Apr 13, 2015 9:53 AM Flag

    Absolutely ridiculous folks. Shorties are digging deeper into this mess and there is no way they can extricate themselves. It is over for the shorts and if they don't realize they are doomed bigtime.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Shorites are toast, they have been playing way too much with this one, it will end today.

    GLTA LONGS!

    Sentiment: Strong Buy

  • You have 1/2 & 4 mg multiple dosages, they always said it should be administered multiple times for a KD.

    They have 3 mg / 4 mg single dosage blinded data which should be coming out soon. Any incremental KD achieved along with the Multi-dosage, makes it the best candidate to achieve a FC for HBV.

    Are partners lining up now, I'm pretty sure it starts today.

    GLTA LONGS!

    Sentiment: Strong Buy

  • That is the potential we are looking into. I'll wait till Jan 2016.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    $8 per share looks to be the DMZ

    by zarlengor Apr 9, 2015 12:40 PM
    jagan1961 jagan1961 Apr 9, 2015 2:06 PM Flag

    On top of it, their computers are churning shares like no other. They made money when they shorted @15-16. Not when they sold @5.

    If anyone don't cover, they will be new Bagholders, will pay a huge price.

    GLTA LONGS!

    Sentiment: Strong Buy

BCE
44.12-0.18(-0.41%)Apr 17 4:07 PMEDT